These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 19483703)

  • 1. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase zero launch.
    Dorey E
    Nat Biotechnol; 2009 Jun; 27(6):496. PubMed ID: 19513040
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of poly(ADP-ribose) polymerase in cancer.
    Plummer ER
    Curr Opin Pharmacol; 2006 Aug; 6(4):364-8. PubMed ID: 16753340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future.
    Gartner EM; Burger AM; Lorusso PM
    Cancer J; 2010; 16(2):83-90. PubMed ID: 20404603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-molecule PARP modulators--current status and future therapeutic potential.
    Penning TD
    Curr Opin Drug Discov Devel; 2010 Sep; 13(5):577-86. PubMed ID: 20812149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug development: moving away from the old habits.
    Ades F; Zardavas D; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
    [No Abstract]   [Full Text] [Related]  

  • 7. PARP inhibitors.
    Plummer R
    Clin Adv Hematol Oncol; 2012 May; 10(5):322-3. PubMed ID: 22706542
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 9. Discovery and SAR of substituted 3-oxoisoindoline-4-carboxamides as potent inhibitors of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
    Gandhi VB; Luo Y; Liu X; Shi Y; Klinghofer V; Johnson EF; Park C; Giranda VL; Penning TD; Zhu GD
    Bioorg Med Chem Lett; 2010 Feb; 20(3):1023-6. PubMed ID: 20045315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.
    Riely GJ
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1803-4. PubMed ID: 22005537
    [No Abstract]   [Full Text] [Related]  

  • 11. [PARP inhibitors for cancer therapy].
    Saito H; Miki Y
    Gan To Kagaku Ryoho; 2011 Jan; 38(1):12-8. PubMed ID: 21368455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitors in breast cancer.
    Telli ML; Ford JM
    Clin Adv Hematol Oncol; 2010 Sep; 8(9):629-35. PubMed ID: 21157412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside.
    Plummer R
    Clin Oncol (R Coll Radiol); 2014 May; 26(5):250-6. PubMed ID: 24602564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Phase 0 trials in drug development.
    Doroshow JH; Kummar S
    Future Med Chem; 2009 Nov; 1(8):1375-80. PubMed ID: 21426052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of anti-cancer drugs.
    Arrondeau J; Gan HK; Razak AR; Paoletti X; Le Tourneau C
    Discov Med; 2010 Oct; 10(53):355-62. PubMed ID: 21034677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic endpoints as clinical trial objectives to answer important questions in oncology drug development.
    Parchment RE; Doroshow JH
    Semin Oncol; 2016 Aug; 43(4):514-25. PubMed ID: 27663483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical poly(ADP-ribose) polymerase inhibitors for the treatment of cancer.
    Lewis C; Low JA
    Curr Opin Investig Drugs; 2007 Dec; 8(12):1051-6. PubMed ID: 18058575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poly(ADP-ribose) polymerase as a drug target for cardiovascular disease and cancer: an update.
    Horvath EM; Szabó C
    Drug News Perspect; 2007 Apr; 20(3):171-81. PubMed ID: 17520094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PARP inhibitors refocus for rebound.
    Schmidt C
    Cancer Discov; 2012 Aug; 2(8):659. PubMed ID: 22886647
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase 0 trials: an industry perspective.
    Eliopoulos H; Giranda V; Carr R; Tiehen R; Leahy T; Gordon G
    Clin Cancer Res; 2008 Jun; 14(12):3683-8. PubMed ID: 18559583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.